Overview

• Researchers have identified a common gut bacterial strain that produces two irisin-like proteins, RORDEP1 and RORDEP2, capable of reshaping hormonal balance.
• RORDEP proteins elevate GLP-1, PYY, and insulin levels while reducing GIP release and directly promoting fat burning.
• In rodent models, administration of RORDEP-producing microbes or isolated peptides led to decreased weight gain, improved glycemic control, and stronger bones.
• GutCRINE’s Phase 1 studies are now enrolling healthy volunteers to assess safety and biological activity of live RORDEP-producing probiotics and RORDEP1 protein.
• The biotech aims within 10 to 15 years to develop second-generation probiotics and modified RORDEP proteins as treatments for obesity, diabetes, cardiovascular disease, and osteoporosis.